What is Blueprint Medicines Corporation (BPMC)?

Blueprint Medicines Corporation (BPMC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BPMC?

The current price of BPMC is $129.46. Prices are updated in real time on Stocks360.

What is BPMC's price-to-earnings (PE) ratio?

BPMC's trailing twelve-month PE ratio is -120.99, based on current price and earnings per share data available on Stocks360.

What is BPMC's market capitalization?

BPMC's market capitalization is $8,360,811,612.00, placing it in the mid-cap tier.

Blueprint Medicines Corporation (BPMC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$129.46

Market Cap

$8.36B

PE (TTM)

-120.99

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.83

Day Range

$129.46 – $129.46

52-wk Range

$73.04 – $129.55

Avg Volume

N/A

Volume

2.98M

Blueprint Medicines Corporation (BPMC) is a publicly traded company in the Healthcare sector. Latest price: $129.46. Market cap $8.36B. Trailing PE -120.99. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 1, 2025

EPS $-0.74 vs est. $-0.42

Missed by $0.32

Proprietary Signals

Signal snapshot temporarily unavailable.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-120.99×
P/S (TTM)	16.43×
P/B	27.25×
PEG	0.58×
P/FCF (TTM)	-42.39×
EV / EBITDA	453.77×
EV / Sales	17.15×
Earnings Yield	-0.82%
Free Cash Flow Yield	-2.36%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$8.73B
Revenue (TTM)	$508.82M
Net Income (TTM)	-$68.93M
Free Cash Flow (TTM)	-$127.13M
Net Debt	$367.09M
Working Capital	$481.88M
Gross Margin	96.04%
Operating Margin	-41.67%
Net Margin	-13.19%
Return on Equity	-31.26%
Return on Invested Capital	-21.72%